CXCL12/CXCR4 blockade induces multimodal anti-tumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer

Authors: Elda Righi¹², Satoshi Kashiwagi¹, Jianping Yuan¹, Michael Santosuosso¹, Pierre Leblanc¹, Rachel Ingraham¹, Benjamin Forbes¹, Beth Edelblute¹, Brian Collette¹, Deyin Xing³, Magdalena Kowalski¹⁴, Maria Cristina Mingari², Fabrizio Vianello⁵, Michael Birrer⁶, Sandra Orsulic³⁸, Glenn Dranoff⁷, and Mark C. Poznansky¹

¹Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital, Charlestown, MA
²Department of Experimental Medicine and IST Cancer Research, Genoa University, Italy
³Molecular Pathology, Massachusetts General Hospital, Boston, MA
⁴Department of Zoology, Clare College, Cambridge, UK
⁵Dept of Haematology, Padua University Hospital, Italy
⁶Gynecological Oncology Cancer Center, Massachusetts General Hospital, Boston, MA
⁷Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA
⁸Women’s Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Running Title: CXCL12/CXCR4 blockade in ovarian cancer

Key Words: CXCL12/CXCR4 axis, AMD3100, tumor progression

Précis: Findings reveal that antagonism of the CXCL12-CXCR4 signaling axis elicits antitumor immunity and prolongs survival in a mouse model of ovarian cancer.
Footnotes:

ER and SK contributed equally to the paper.

MCP and ER were supported by Public Health Service Grants RO1 AI49757, the Marsha Rivkin Center for Ovarian Cancer Research, and philanthropic funds. SO was supported by the Marsha Rivkin Center for Ovarian Cancer Research and the Garber Award.

Corresponding authors: Elda Righi and Mark C. Poznansky, Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital (East), Charlestown, MA 02129, Phone: 617-724-6375, Email: erighi@partners.org, mpoznansky@partners.org
Abstract

The chemokine CXCL12 and its receptor CXCR4 are expressed widely in human cancers including ovarian cancer, where they are associated with disease progression at the levels of tumor cell proliferation, invasion, and angiogenesis. Here we used an immunocompetent mouse model of intraperitoneal papillary epithelial ovarian cancer to demonstrate that modulation of the CXCL12/CXCR4 axis in ovarian cancer has multimodal effects on tumor pathogenesis associated with induction of antitumor immunity. siRNA-mediated knockdown of CXCL12 in BR5-1 cells that constitutively express CXCL12 and CXCR4 reduced cell proliferation in vitro and tumor growth in vivo. Similarly, treatment of BR5-1-derived tumors with AMD3100, a selective CXCR4 antagonist, resulted in increased tumor apoptosis and necrosis, reduction in intraperitoneal dissemination, and selective reduction of intratumoral FoxP3+ regulatory T-cells (T-regs). Compared to controls, CXCR4 blockade greatly increased T cell-mediated antitumor immune responses, conferring a significant survival advantage to AMD3100-treated mice. In addition, the selective effect of CXCR4 antagonism on intratumoral T regulatory cells was associated with both higher CXCR4 expression and increased chemotactic responses to CXCL12, a finding that was also confirmed in a melanoma model. Together, our findings reinforce the concept of a critical role for the CXCL12/CXCR4 axis in ovarian cancer pathogenesis, and they offer a definitive preclinical validation of CXCR4 as a therapeutic target in this disease.
Introduction

Chemokines and their cognate receptors have been shown to play a role in favoring tumor growth, progression and immune escape through multiple mechanisms(1-6). CXCL12 and its receptor, CXCR4, constitute a chemokine-receptor axis that is known to be expressed in various tumors and to correlate with poor clinical outcome(7-14). CXCL12 is expressed by primary human ovarian cancer and has been detected in tumor tissue and ascitic fluid (2,15,16), while CXCR4 is the only chemokine receptor shown to be constitutively expressed in epithelial ovarian cancer(15,16). CXCL12 can stimulate ovarian cancer cell proliferation by direct activation of protein kinases PKB and MAPK, and by indirect protection of cancer cells from apoptosis (16-18).

CXCL12 produced by tumor tissue and surrounding stroma stimulates VEGF-mediated angiogenesis(5, 19) and the recruitment of endothelial progenitor cells from the bone marrow(20). CXCL12 can also mediate tumor invasion and metastasis by impairing cell adhesion to integrins, attracting CXCR4+ cancer cells and increasing matrix metalloproteinase expression(8, 15,16,21). CXCL12 has also been demonstrated to repel tumor-specific effector T-cells and to recruit suppressive cell populations at tumor sites, including IL-10-producing plasmacytoid dendritic cells, T-regs, and myeloid-derived suppressor cells (MDSCs)(22-25).
We proposed that modulation of the CXCL12/CXCR4 axis in ovarian cancer would impact multiple aspects of tumor pathogenesis including immune dysregulation. Therefore this ligand/receptor axis would provide an attractive therapeutic target. The availability of an immune competent murine model of intraperitoneal papillary epithelial ovarian cancer derived from a syngeneic cell line that constitutively expresses CXCL12 and CXCR4 and the existence of a clinically validated, highly specific CXCR4 antagonist, AMD3100, facilitated this approach(26, 27). To date, AMD3100 has been tested in vivo in ovarian cancer in the context of its impact on tumor growth and dissemination in immune deficient mice(21). Knocking down CXCL12 expression or CXCR4 blockade with AMD3100 led to increased tumor cell apoptosis and reduction in tumor growth, peritoneal dissemination and angiogenesis. CXCR4/CXCL12 blockade also lead to a selective reduction in intratumoral T-regs as compared to CD8+ T-cells and increased anti-tumor immunity. These anti-tumor effects were associated with significantly prolonged survival. The selective effect of CXCR4/CXCL12 blockade on intratumoral T-regs was associated with significantly greater expression of CXCR4 and chemotactic responses to CXCL12 of this T-cell subpopulation compared to CD8+ T-cells. These findings support the critical role of the CXCL12/CXCR4 axis in ovarian cancer pathogenesis and immune evasion and provide validation for a new therapeutic target in this disease.
Methods

Animal models and cell lines
Tumor generation involved a single intraperitoneal injection of the syngeneic cancer cell line, BR5-1 (1x10^7 cells per mouse), into five-week-old FVB/NJ mice (Bar Harbor, ME)(28), and was consistently first evident after three to five weeks via abdominal distension secondary to malignant ascites. Tumor-bearing mice were euthanized at the endpoint when there were signs of distress, including fur ruffling, rapid respiratory rate, hunched posture, reduced activity, and progressive ascites formation. At necropsy, tumor weight, volume of ascites, and peritoneal dissemination were measured and lungs, brain, and liver were examined for metastasis by visual inspection. A second tumor model, B16F10 murine melanoma, was used as described previously (see Supplemental Methods)(29). All measurements were performed in a blinded manner, (to control or experimental group), and all animal experiments were executed according to Public Health Service Policy on Humane Care of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Massachusetts General Hospital.

CXCL12 knockdown using RNAi vector
CXCL12 expression knockdown in BR5-1 cells was achieved by transducing the cells with MISSION lentiviral transduction particles (Sigma-Aldrich) through the use of five different shRNA sequences targeting CXCL12 (see Supplemental Methods).

Cell proliferation and CXCL12 quantitation
Cell proliferation was measured by manual counting and by using the Premix WST-1 Cell Proliferation Assay System (Clontech Laboratories, Mountain View, CA). In certain experiments, 100 ng/ml of exogenous recombinant murine CXCL12 (Peprotech, Rocky Hill, NJ) was added to the culture of CXCL12 knocked-down BR5-1 cells (kdBR5-1) in fresh media at 0, 24, 48, and 72 hr. CXCL12 was measured in cancer cell culture supernatants using a CXCL12-ELISA kit (R&D).

**AMD3100 treatment in vivo**

Administration of AMD3100 into mice was achieved using osmotic minipumps (Alza, Palo Alto, CA) implanted dorsolaterally under the skin. For the murine ovarian cancer model, animals were treated with AMD3100 or vehicle (PBS) using two different schedules; schedule A - treatment began upon the development of ascites either for 3 days (for time-matched study) or until evident signs of distress as described above (for survival study), schedule B - treatment began two weeks after intraperitoneal injection of tumor cells either for 14 days (for time-matched study) or until evident signs of distress as described above (for survival study). For the murine B16F10 melanoma model, AMD3100 treatment was initiated when tumors reached 4 mm in mean diameter either for 4 days (for time-matched study) or until tumors reached a size >12mm in diameter or the mice showed signs of distress (for survival study). The details of the treatment are described in the Supplemental Methods. All monitoring of animal survival and tumor progression was performed in a manner that was blinded to the observer.

**Quantitation of tumor vessel density by immunofluorescence**
Mice were euthanized at day 3 after tumor development, at which point the sizes of the tumors analyzed were comparable in the treatment group vs. controls. Tumor vessel density was determined and scored in a blinded manner using fluorescein-labeled lectin (Vector lab, Burlington, MA) and image analysis (Carl Zeiss LSM5 Pascal, Carl Zeiss North America, MO Zeiss) and Image J 1.43 freeware (NIH, MD) as previously described (30).

Quantitation of tumor infiltrating lymphocytes (TILs) by immunofluorescence

Immunofluorescence analysis of tumor infiltrating CD8(CTLs) and FoxP3(T-regs) positive cells was performed. T-cells were visualized using confocal microscopy and scored in a blinded manner using Image J 1.43 freeware (see Supplemental Methods).

Quantitation of apoptosis using TUNEL staining

TUNEL staining was performed on 10µm-thick tumor sections prepared as described in the previous section using the In situ Cell Death Detection Kit TMR Red (Roche). Slides were imaged and analyzed using Image J and were blinded to the analyzer.

Flow cytometry

For TIL subpopulation analysis, mononuclear cells including tumor cells, stromal cells and immune cells derived from disaggregated tumor tissue were separated by centrifugation on Ficoll Hypaque, and directly stained with fluorophore-conjugated anti-CD3, anti-CD8, anti-CD4, anti-CD25, anti-FoxP3, and anti-CXCR4 antibodies (BD Bioscience). Cell subpopulations, including CD3+CD4+ T helper cells, CD3+CD8+ cytotoxic T-cells (CTL) and CD4+CD25+FoxP3+(T-
regs) were quantified as a percentage of cell per gram of tumor tissue through examination of both positive control and fluorescence-minus-one gating strategy (FMO)(31). For in vitro assessment of tumor-specific T-cell function, splenocytes and TILs isolated and prepared as single-cell suspensions were plated and pulsed with tumor lysates, Her2/neu peptide (0.1 µg/ml, PDSLRDLSVF, EZBiolab, Westfield, IN)(32), or medium alone for 18 hr when Golgi Plug (BD Bioscience) was added (0.75 µl/well) for 6 hr, stained with anti-Granzyme B (R&D Systems), and analyzed on a 3 laser LSRII BD Biosciences) (see Supplemental Methods).

*T regulatory cell depletion and CD8+ cell isolation*

Magnetic beads were used to separate T-regs and CD8+ cells (MACS, Milteny Biotech, Auburn, CA) yielding a population with >95% purity. T-reg depleted cells (CD4+CD25-) were plated, stimulated and stained as described above.

*Transmigration assay*

T-regs and CD8+ cell migration was measured using Transwells (96-well format, 3-micron pore size; ChemoTx System, Neuro Probe Inch, Gaithersburg, MA) as previously described(33) in CXCL12 concentrations (5ng/ml, 50ng/ml, 500ng/ml, and 5µg/ml), and in the presence or absence of AMD3100 (1µg/ml) or pre-incubation with 100 ng/ml pertussis toxin (PTX; Sigma) for 1hr at 37°C.

*Statistical analysis*
All of the results are expressed as mean ± SEM. Differences between treatment groups were determined by the Mann Whitney test and in other numerical variables by unpaired $t$ test with a $P$ value of $<0.05$ considered significant. All statistical analyses were independently performed on datasets by Dr. Gebremichael at the Harvard School of Public Health.
Results

**CXCL12 knockdown impacts BR5-1 proliferation in vitro and tumor growth in vivo**

CXCL12 has been shown to stimulate ovarian cancer cell proliferation in vitro(16). We used the murine ovarian cancer cell line BR5-1, which constitutively expresses CXCL12 and CXCR4, to observe the effect of RNAi-mediated CXCL12 silencing on tumor growth. CXCL12 levels from wild-type BR5-1 cells(wtBR5-1), RNAi-transfected, CXCL12 knocked-down BR5-1 cells(kdBR5-1), and scrambled-RNAi transfected BR5-1 cells(scrBR5-1) were quantitated using an ELISA immunoassay(Figure 1A). Similar levels of CXCL12 were released by wtBR5-1 and scrBR5-1 (1.05 ± 0.19 ng/ml and 0.85 ± 0.09 ng/ml) while CXCL12 from kdBR5-1 was negligible (<0.02 ng/ml, *P* < 0.0001). CXCR4 expression was not significantly different among wtBR5-1, kdBR5-1, and scrBR5-1 (Figure 1B). KdBR5-1 proliferated at a significantly slower rate compared to wtBR5-1 and scrBR5-1 (*P* < 0.0001, Figure 1C). The results were confirmed using a WST-1 proliferation assay, showing a significantly higher absorbance in wtBR5-1 compared to kdBR5-1 at 48 hr (absorbance ratio 12.5 ± 0.23 vs. 3.37 ± 0.30 respectively, *P* <0.001, not shown). Addition of exogenous CXCL12 significantly increased kdBR5-1 proliferation to a level comparable to wild type (Figure 1D). Apoptosis was excluded as a mechanism responsible for the reduced kdBR5-1 cell proliferation (Figure 1E), thus confirming direct effect of CXCL12 on ovarian cancer cell proliferation(16).

To test if defective CXCL12 production was maintained in vivo, cancer cells derived from wtBR5-1(WT) and kdBR5-1 tumors(RNAi) were grown for 48 hr in media. Quantitation of CXCL12 in supernatants showed results comparable to in vitro data, with CXCL12 < 0.02 ng/ml.
in tumor cells extracted from kdBR5-1 injected mice and CXCL12 levels of 1.2 ± 0.10 ng/ml in
tumor cells extracted from wtBR5-1 tumors. Furthermore, RNAi tumors displayed a marked
reduction of CXCL12 (stained red in Figure 1F) compared to WT tumors via
immunofluorescence. Small numbers of cells expressing CXCL12 were detected and thought to
be due to the infiltration of CXCL12-expressing stromal and endothelial cells (white arrows,
Figure 1F) in the tumor microenvironment.

FVB/NJ mice injected with wtBR5-1 normally generate intraperitoneal tumors in three to five
weeks. The time interval between tumor implantation and appearance of ascites was found to be
significantly higher in kdBR5-1 injected mice compared to wtBR5-1 and scr-BR5-1 injected
mice (53 ± 5.5 days vs. 33 ± 2.1 and 32 ± 3.3 days respectively, P < 0.05, Supplementary Figure
1A). A reproducible ‘survival window’ was defined between the first clinical sign of disease
(abdominal swelling secondary to ascites formation) and euthanasia required by advanced
clinical condition. The overall survival was significantly longer in kdBR5-1-injected mice
compared to wtBR5-1-injected mice (8.7 ± 1.8 days vs. 3.4 ± 0.4 days respectively, P < 0.005,
Figure 1G). Mice injected with scrBR5-1 had similar survival windows (3.3 ± 0.5 days)
compared to wtBR5-1-injected mice.

AMD3100 treatment prolongs mouse survival and reduces dissemination of tumors

Mice were treated with AMD3100 either at the onset of ascites until the end-stage time point
(schedule A) in order to simulate the treatment in human disease(34), or from day 15 after the
implantation of tumor cells (schedule B). AMD3100 treatment schedules were based on previous
pharmacokinetic evaluations to maintain steady serum levels (35). AMD3100 treatment on schedule A resulted in a two-fold increase in survival compared to PBS-treated mice (6 days vs. 3 days, $P < 0.05$) (Figure 2A), and higher overall survivals were reported in the AMD3100 treated mice vs. controls, (38 days ± 1.1. vs. 32 days ± 1.5, $P < 0.05$) (Figure 2B). In a separate experiment, AMD3100-treated and PBS-treated mice were euthanized at day three from the onset of clinical signs to compare total tumor mass, volume of ascites, and tumor dissemination (Figure 2 C-E). Mean tumor weight and amount of ascites were lower in AMD-treated compared to PBS–treated mice (1.3 ± 0.23 g and 4.4 ± 0.4 ml vs. 0.8 ± 0.17 g and 3.6 ± 0.4 ml, respectively) (Figure 2 D- E), although these differences were not significant.

BR5-1 injection robustly results in multiple tumor nodules growing on organ surfaces without significant invasion. Sites of tumor spread include the mesothelial lining of the peritoneum, intestines, spleen, and diaphragm, but not the lungs(28). Tumor dissemination was compared between AMD3100-treated vs. PBS-treated mice (Figure 2 F-G) and classified as localized (localizations ≤ 3), limited (6 < localizations > 3, with no visible masses on mesentery and diaphragm), or disseminated (localizations ≥ 6, including mesentery and diaphragm). The percentage of mice with tumor deposits on organ surfaces at necropsy was lower in AMD3100-treated compared to PBS-treated mice. While all AMD3100-treated mice had localized or limited tumors, 70% of the tumors in PBS-treated mice fell under the disseminated category.

In schedule B, when the treatment was started at day 15 after tumor implantation, a significant delay in the onset of ascites was recorded in the AMD3100 treated mice vs. controls (21 ± 0.5
days vs. 24 ± 1.3 days, \( P < 0.05 \). An increase in survival in AMD3100 treated versus control treated animals was observed (3.6 days vs. 7 days, Figure 2H) as well as higher overall survival times (41 ± 2.1 days vs. 36 ± 0.5 days, \( P < 0.05 \)) (Supplemental Figure 1B). Tumor dissemination in schedule B examined five weeks after the tumor injection was comparable to those on schedule A (Figure 2I).

CXCL12/CXCR4 manipulation markedly reduces tumor angiogenesis

CXCL12 is a pro-angiogenic factor in ovarian cancer via upregulation of VEGF, which in turn increases CXCR4 expression by endothelial cells (19, 36). Vessel density was significantly lower in AMD3100 tumors and RNAi tumors compared to PBS-tumors (Figure 3A and B: 91.23 ± 17.57 vessels/mm² and 71.11 ± 28.73 vessels/mm² vs. 167.84 ± 27.92 vessels/mm² respectively, AMD3100 vs. PBS - \( P < 0.05 \); RNAi vs. PBS - \( P < 0.05 \)). SCR tumors displayed similar vessel density (111.11 ± 11.07 vessels/mm²) to PBS-tumors.

AMD3100 treatment increases tumor apoptosis and necrosis

It has been previously reported that CXCL12-mediated inhibition of the NF-κB/TNFα apoptotic pathway (17, 18) affords in vivo protection from tumor apoptosis and that this can be impaired via CXCR4 inhibition (37, 38). Here, significantly higher numbers of apoptotic cells were found in AMD3100 tumors compared to PBS-tumors (90.86 ± 17.99 cells/mm² vs. 37.18 ± 11.60 cells/mm², \( P < 0.05 \)) (Figure 4 A-B). RNAi tumors showed a non significant increase in apoptotic cells compared to controls (97.35 ± 46.5 cells/mm²), suggesting a compensatory role for stromal-derived CXCL12 in these tumors. H&E stained selected tumor tissues from
AMD3100-treated and PBS-treated mice showed areas of necrosis in 50.0% of the AMD3100 tumor sections, while PBS tumor sections appeared microscopically negative for necrotic tissue (Figure 4C).

**CXCR4 antagonism selectively reduces intratumoral FoxP3+ T-cell infiltration in comparison to CD8+ T-cells**

CXCL12 can act as both a chemoattractant and a chemorepellent for T-cell subpopulations in a concentration and CXCR4 dependent manner in tumor models(25). Therefore, we examined the effect of the manipulation of the CXCL12/CXCR4 axis on intratumoral T-cell trafficking in this model of ovarian cancer. CD8+ T-lymphocyte infiltration was not significantly different in PBS-treated, kdBR5-1-injected, and AMD3100-treated mice via immunofluorescence (Figure 5A, upper panels and 5B) and flow cytometry (CD3+CD8+: 11.09 ± 0.20%, 10.44 ± 1.18 %, 9.54 ± 0.16 % and CD3+CD4+: 42.1 ± 2.39 %, 40.53 ± 0.15 %, 40.33 ± 2.30 %, respectively). In contrast, RNAi tumors and AMD3100 treatment resulted in a significant 4 to 5-fold reduction in FoxP3+ T-cells compared to PBS-tumors as determined by immunohistochemistry (18.77 ± 7.29 cells/mm² and 14.46 ± 4.48 cells/mm² vs. 76.0 ± 25.02 cells/mm², P < 0.05, Figure 5A, lower panels and 5C) and flow-cytometry (Figure 5D). No differences were detected in the spleen for CD3+CD8+, CD3+CD4+ and CD4+CD25+FoxP3+ cells among PBS-treated, kdBR5-1-injected, and AMD3100-treated mice (data not shown). In order to determine whether this was the result of selective FoxP3+ T-cell redistribution(39) or an alteration in TIL trafficking(25), thymus and spleens were obtained from tumor-bearing mice and stained for FoxP3 expression. No significant differences were detected in PBS-treated (1008.23 ± 196.15 cells/mm² and 69.54 ± 21.77...
cells/mm²) vs. AMD3100-treated mice with regards to the number of FoxP3+ T-cells in these tissues (948.15 ± 156.03 cells/mm² and 153.40 ± 86.65 cells/mm², Figure 5E). AMD3100 treatment resulted in a 6-fold increase in the CD8+/FoxP3+ ratio, a parameter correlated with increased survival in ovarian cancer(40), compared to control PBS treated animals (3.12 and 3.50 vs. 0.58 respectively, \( P < 0.01 \), Figure 5F).

**AMD3100 treatment selectively increases tumor-specific T-cell responses and impairs T-reg migration in vitro**

To test if the differential distribution of T-reg was associated with impaired tumor-specific T-cell function, we analyzed the in vitro production of Granzyme B in T-lymphocytes extracted from spleen and tumors in AMD3100-treated and PBS-treated mice as described above. Splenocytes and TILs were stimulated with tumor lysates and Her2/neu specific peptide for 24 hr and then analyzed for the intracellular expression of Granzyme B using flow-cytometry. Her2/neu was shown to be expressed by BR5-1 using flow-cytometry (data not shown). Granzyme B production was significantly higher in TILs from AMD3100-treated compared to PBS-treated mice for both tumor lysates and Her2/neu peptide stimulation for CD4+ and CD8+ T-cells (Figure 6 A-B). To assess the impact of T-reg on T-lymphocyte function, splenocytes and TILs were depleted of T-reg using magnetic beads. Depleted CD4+CD25- and non-depleted CD4+CD25+ cells were stimulated as before, and Granzyme B expression was determined using flow cytometry. Non-depleted CD4+ TILs from AMD3100 tumors showed higher Granzyme B production compared to PBS-tumors, whereas T-reg depleted TILs from PBS-tumors demonstrated increased Granzyme B production compared to non-depleted TILs from PBS.
treated tumors (Figure 6 C-D). No differences in Granzyme B production were observed in the spleen derived T-cell populations for either AMD3100 or PBS-treated tumors (Figure 6D and data not shown).

We observed that intratumoral T-regs consistently express higher CXCR4 levels compared to CD4+CD25- and CD8+ cells (Figure 6E-F). We then examined the migratory responses of T-regs and CD8+ cells to gradients of CXCL12 in vitro. We showed that T-regs from both tumors and spleen underwent chemotaxis in response to chemotactic gradients of the CXCL12 with a classical bell shaped dose-response curve. Addition of AMD3100 or pre-treatment of cells with Pertussis toxin (PTX) significantly impaired G-coupled, CXCR4-mediated T-reg cell chemotaxis (Figure 6G-H), while AMD3100 did not prevent CD8+ migration towards CXCL12 (Figure 6I). These data support the view that differential expression of CXCR4 may selectively affect the intratumoral trafficking of regulatory versus effector cells towards intratumoral CXCL12 gradients.

**CXCL12/CXCR4 antagonism using AMD3100 selectively impacts T-regs infiltration in a second murine tumor model**

To test the impact of CXCL12/CXCR4 axis blockade on T-regs infiltration in a second solid tumor, we employed the B16F10 murine melanoma model. Previous reports reveal that B16 melanoma cells express both CXCR4 and CXCL12 (41) and have assessed the effect of CXCR4 antagonists on tumor spread (10). To test the effect of CXCL12/CXCR4 manipulation on T-cell infiltration into melanomas, osmotic pumps delivering AMD3100 were implanted as described in
the Methods section. We observed a significant decrease of CD4+CD25+ and CD4+CD25+FoxP3+ T-cells in the AMD3100 treated tumors compared to controls (1277.28 ± 36.73 T-cells/g and 202.56 ± 29.14 T-cells/g vs. 3494.27 ± 831.46 T-cells/g and 573.55 ± 111.40 T-cells/g, \( P < 0.05 \), Figure 7A), while the CD8+ TIL count was not significantly different between the experimental group and controls (1569.28 ± 599.99 T-cells/g vs. 3337.51 ± 687.12 T-cells/g, \( P = 0.89 \), Figure 7A). Intratumoral T-regs were shown to express higher levels of CXCR4 compared to CD8+ cells (Figure 7B). These data are consistent with those generated in the ovarian cancer model and supports the view that the antagonism of the CXCR4/CXCL12 axis results in selective T-reg depletion compared to CD8+ T-cells potentially as a result of higher levels of CXCR4 expression on the regulatory T-cell subpopulation. Tumor growth delay at the levels of 4 and 8 times the initial volume was 2.9 ± 0.6 days and 4.7 ± 1.5 days in control tumors (n=11), and 2.7 ± 0.7 days and 4.3 ± 1.5 days in AMD treated tumors (n=12), respectively. There was no significant difference in the rate of tumor growth or in overall survival between the groups, which is consistent with reports that the CXCL12/CXCR4 axis does not impact B16F10 melanoma cell proliferation(42) and that depletion of T-regs alone is not sufficient to promote tumor eradication in the B16 melanoma model.
Discussion

This first-of-its-kind study confirms that blockade of the CXCR4/CXCL12 axis alone can reduce ovarian tumor growth and peritoneal dissemination, resulting in a significant survival advantage in immunocompetent mice. The murine model that was used reproduces a clinical sequence of events from the detection of ascites to the appearance of disseminated intraperitoneal disease that resembles the progression of the most common form of papillary epithelial ovarian cancer in humans. In this context, we investigated the ability of the CXCL12/CXCR4 axis blockade to target multiple aspects of tumor progression, including cancer growth, angiogenesis, and tumor-specific immune-dysregulation.

This study confirmed that CXCL12 directly impacts cancer cell proliferation in this model. When CXCL12 was knocked-down in BR5-1 cells, which natively express both CXCL12 and CXCR4, we observed a deceleration of tumor growth in vivo and a significant reduction in tumor cell proliferation in vitro that was reversed by adding exogenous CXCL12. Furthermore, AMD3100-treated tumors had increased tumor cell apoptosis and tumor necrosis compared to controls, which is consistent with published data demonstrating that AMD3100-treatment can abrogate CXCL12-mediated protection by apoptosis in cancer and reduce the number of intraperitoneal masses in nude mice.

Tumor-derived CXCL12 plays a part in the trafficking of pro-angiogenic cells (i.e., plasmacytoid dendritic cell) and the induction of pro-angiogenic factors (i.e. CCL8) in the tumor microenvironment. VEGF and CXCL12 have been shown to act synergistically to induce
CXCR4 expression and migration of vascular endothelial cells(19). In this study, impaired vascularization in the RNAi and AMD3100 treatment groups was observed. Tumor angiogenesis is also known to contribute to tumor immune escape through multiple mechanisms, including suppression of adhesion molecule expression, reduction of tumor-specific CTL function and APC activation, and induction of intratumoral T-reg localization(47,48). Therefore the anti-angiogenic effect that AMD3100 elicited in this study may be associated with a reduction of both tumor growth and dissemination as well as a partial correction of tumor immunity.

This model of ovarian cancer in an immunocompetent mouse, allowed us to demonstrate for the first time that AMD3100 results in a significant and selective 4- to 5-fold reduction of FoxP3+ cells in ovarian tumors that was not associated with either a change in the distribution of T-regs in other organs (i.e., spleen and thymus) or a diminution of intratumoral CD8+ T-cells. CXCL12-mediated mechanisms hypothesized to be involved in immune suppression are either the repulsion of anti-tumor effector T-cells or the active recruitment of immunosuppressive cells (25,39). The preferential accumulation of tumor-specific, T-cell suppressive T-regs in ovarian cancer tissue and ascites was previously correlated with poor survival(49). Our results show that AMD3100 differentially blocks intratumoral T-reg infiltration and migration in comparison to CD8+ T-cells in vivo and in vitro, respectively. We also found that this was associated with the finding that intratumoral T-regs express significantly higher levels of CXCR4 than CD8+ T-cells. These findings were recapitulated in a second tumor model(49). Furthermore, we demonstrated that depletion of T-regs from TILs reversed an apparent immunosuppressive effect.
on tumor antigen specific Granzyme B production in vitro, supporting the concept that exclusion of T-reg from the intratumoral milieu may augment local anti-tumor immunity(50).

These findings reveal a new mechanism for modulating intra-tumoral T-cell subsets that compares favorably with other therapeutic strategies. In this study, AMD3100 treatment resulted in a 6-fold increase in the intratumoral Teff/Treg ratio. This highly significant change was associated with significantly improved cytotoxic T-cell function in tumor tissue, prolonged survival in this model and is consistent with recent approaches to depleting intratumoral T-reg (51,52). Tube, S. et al. reported that the CD8/Treg ratio in TC-1/anti-CTLA-4-gamma1 expressing tumors was increased by 6.5-fold compared to control TC-1 tumors(52). Yoshimura K. et al. reported that administration of an engineered hepatic-targeting Listeria monocytogenes (LM) with cyclophosphamide lead to a 5-fold increase in the Teff/Treg ratio in a murine model of colorectal cancer metastasis to the liver(51). Importantly, we clearly demonstrated that the CXCR4 antagonism induced selective reduction of intratumoral T-reg without affecting systemic T-reg and intratumoral CD8+ T effector cells. Conventional strategies to reduce the number of intratumoral T-reg including the systemic application of anti-CD25 antibody and cyclophosphamide do not specifically target T-reg, and therefore also deplete T effector cells. Furthermore, such strategies have significant drawbacks, including toxicity and induction of autoimmunity due to the systemic elimination of T-reg(53). In our study we have successfully identified an effective strategy to selectively deplete intratumoral T-reg, resulting in prolonged survival in a murine model of ovarian cancer.
In summary, these data generated in an immunocompetent syngeneic and orthotopic murine model, lend important support to the view that the CXCL12/CXCR4 axis plays multiple roles in the pathogenesis of ovarian cancer. This study, demonstrates a new role for this axis in the selective trafficking of T-regs into the tumor in addition to reaffirming its established roles in tumor apoptosis, growth and angiogenesis. We also show that these multimodal effects of specific single agent CXCR4/CXCL12 axis blockade in this model of ovarian cancer are associated with a significantly prolonged survival and reductions in indices of tumor progression. The availability of a safe, effective and clinically applicable CXCR4 antagonist in AMD3100 adds both to the direct clinical translatability of this study and to the enthusiasm amongst clinicians to explore the use of this agent as an adjunct to conventional chemotherapy, including taxol in platinum resistant disease, or in combination with other immunotherapies aimed at enhancing CD8+ T-cell responses in human ovarian cancer.
Acknowledgements:

We thank Dr. Gebremichael at the Harvard School of Public Health for help with the independent statistical analysis of datasets. We thank Christine Linton, Brett Kodish, Haaris Beg, and Federico Ivaldi for technical support.
References


Figure legends

Figure 1

Effect of CXCL12 knockdown on cell proliferation in vitro and in vivo (A) CXCL12 ELISA results from cell supernatants of wtBR5-1, kdBR5-1, and scrBR5-1 (mean ± SEM, n = 3). (B) Cell surface expression of CXCR4 on wtBR5-1, kdBR5-1, and scrBR5-1 cells (n=3). (C) Proliferation curves comparing CXCL12-producing cells, wtBR5-1 and scrBR5-1, kdBR5-1, **P<0.001 (mean ± SEM, n=3). (D) Proliferation curves of wtBR5-1 and kdBR5-1 cells in standard media (DMEM with 10% FBS) and RNAi cells in media containing 100ng/ml of exogenous recombinant CXCL12 (Exo CXCL12) *P < 0.005. (E) Annexin V staining of wtBR5-1 and kdBR5-1 cells (n=3). (F) Confocal imaging of CXCL12 expression (red) in WT vs. RNAi tumors in vivo. Perfused vessels (green) (fluorescein-labeled lectin) and nuclear counterstaining (blue) (To-Pro-3). In the RNAi image CXCL12 stromal expression indicated by arrows. Scale bar: 50 µm. (G) Kaplan-Meier survival analysis. FBV/NJ mice were followed up for appearance of ascites and tumor progression to endpoint described in Methods section for wtBR5-1 (WT) vs. kdBR5-1 (RNAi) tumor (four to six mice, two independent experiments, *P<0.05).

Figure 2

Effect of AMD3100 treatment on tumor progression and mice survival. (A-G) AMD3100 or PBS was delivered into FVB/NJ mice with wtBR5-1 tumors at onset of ascites (schedule A). (A-B) Survival curves (A) from the onset of ascites and (B) from the time of tumor cell injection. (n =
10 per group, \( *P<0.05 \). (C-E) Effect of AMD3100 treatment on tumor weight and ascites formation. Tumor bearing mice were treated with AMD3100 or PBS under schedule A (n = 8 from three experiments) and euthanized at day 3 post ascites. (C) Representative mice from AMD3100 and PBS groups are shown. (D) Total tumor weight and (E) ascites volumes were measured. (F) Bar graph representing the percentage of mice with visible tumor deposits on organs at necropsy (n = 10 per group; \( *P<0.01 \)). (G) Tumor dissemination. Classification: localized (localizations \( \leq 3 \)), limited (6 < localizations > 3, with no visible masses on mesentery and diaphragm), and disseminated (localizations \( \geq 6 \) including mesentery and diaphragm localization), \( *P<0.01 \). (H-I) AMD3100 or control PBS delivered for 15 days after tumor cell injection (schedule B). (H) Survival curves of the mice treated under schedule B from the onset of ascites showing that AMD3100 treated mice increased survival window (n = 6, \( *P<0.01 \)) and (I) reduced tumor dissemination (n = 6, \( P<0.05 \)).

**Figure 3**

Effect of CXCL12/CXCR4 manipulation on tumor angiogenesis. (A) Confocal imaging of tumor angiogenesis from PBS (n = 8), AMD3100 (n = 8), and RNAi (n = 6) tumors. Functional vessels are visible in green, and blue represents nuclear counterstaining (To-Pro-3). Scale bars: 50\( \mu \)m. (B) Vessel quantitation expressed as density per mm\(^2\). Microvascular density was quantified from five randomized fields using Image J, and expressed as average\( \pm \)SEM, \( *P<0.05 \).

**Figure 4**

(A) Confocal imaging of tumor apoptosis in tumor bearing mice treated with AMD3100 (n = 8) or
PBS (n = 7) (schedule A). Vessels (green) and nuclei (blue) were visualized (To-Pro-3). Apoptotic cells (red) were identified using TUNEL staining. (B) quantified from five randomized fields using Image J, *P < 0.05. (C) H&E staining of PBS and AMD3100 tumor sections demonstrating necrosis in AMD3100 tumors. Scale bar: 50 µm.

**Figure 5**

(A-C) Effect of CXCL12/CXCR4 manipulation on intratumoral FoxP3+ and CD8+ lymphocyte infiltration. (A), upper panels; confocal imaging of intratumoral CD8+ cells (red) from PBS (n = 7), AMD3100 (n = 7), and RNAi (n = 5) tumors. (A), lower panels; confocal imaging of intratumoral FoxP3+ cells (red) from PBS (n = 3), AMD3100 (n = 11), and RNAi (n = 7) tumors vessels (green) and nuclei (blue). Scale bars: 50 µm. The number of CD8+ and FoxP3+ cells was quantified from five randomized fields, *P < 0.05. (B) CD8+ cell, (C) FoxP3+ count. (D) Representative results of three independent flow analyses on four to six mice per group and reported as percentage of CD4+CD25+FoxP3+ TILs (450,000 events collected). TILs were stained with anti-CD4, anti-CD25, and anti-FoxP3. (E) FoxP3+ cell count per mm² from thymus and spleen (n = 3). (F) CD8+/FoxP3+ ratios, **P < 0.01.

**Figure 6**

Effect of tumor-specific T-cell function and migration after AMD3100 treatment. (A-B) TILs from AMD3100 and PBS groups were stimulated with tumor lysates (Lysed) or Her2/neu peptide (Her2/neu) (n = 3 per group, 450,000 flow events collected). Results are reported as difference between non-stimulated (media alone) and stimulated cells and expressed as frequency.
of parent CD4+(A) or CD8+ cells(B), *P<0.05. (C)TILs were depleted of T-regs and stimulated for 24hr. Granzyme B production was measured(n = 6 per group, 450,000 flow events collected). Results are reported as difference between non-stimulated(media) and stimulated, adjusted for the number of CD4+ cells in depleted and non-depleted groups, and reported as percentage of total CD4+ cells, *P<0.05. (D)Representative flow data relating to T-cell function in splenocytes from PBS and AMD3100 groups showing no difference in Granzyme B production in CD8+ cells per each stimulation condition(350,000 events per condition). (E) Expression of CXCR4 on intratumoral non-depleted(CD4+CD25+FoxP3+), depleted cells (CD4+CD25-) or (F) on CD8+ cells. CXCL12 induced transmigration of tumor derived T-regs(G and H) and intratumoral CD8+ cells(I). T-regs migration to CXCL12 was tested in a transwell assay. Mean ± SEM of three wells from five experiments are shown. Transmigration index was calculated as the ratio between migrated cells in the lower chambers and the average of the random migrated cells (media alone in the upper and lower chambers) ± SEM. *P<0.05, **P<0.005.

**Figure 7**

Effect of AMD3100 on B16F10 subcutaneous tumors in C57/BL6 mice. (A)Intratumoral CD8+ cells(n=6) and T-regs infiltration(n=6) was assessed by flow cytometry(750,000 events) and expressed as number of cells/gram of tumor. (B)Lower CXCR4 expression was shown on intratumoral T-regs cells (left panel) compared to T-effector cells (right panel)(1x10^6 events recorded)(representative histograms shown).
Figure 1

A

CXCL12 (pg/ml)

wtBR5-1        kdBR5-1        scrBR5-1

B

SCC

wtBR5-1        kdBR5-1        scrBR5-1

CXCR4

C

Total Cell Number

0h   24h   48h   72h

wtBR5-1    kdBR5-1    scrBR5-1

D

Total Cell Number

0h   24h   48h   72h

wtBR5-1    kdBR5-1    Exo-kdBR5-1

E

Cell Count

wtBR5-1    kdBR5-1

G

Percent Survival

Days Post-Ascites

WT    RNAi

F

Anti-CXCL12

WT    RNAi

Negative Control

Downloaded from cancerres.aacrjournals.org on April 19, 2017. © 2011 American Association for Cancer Research.
Figure 2

A

Percent Survival

Days Post-Ascites

B

Percent Survival

Days Post-Tumor Injection

C

D

Tumor weight (g)

PBS

AMD3100

PBS

AMD3100

E

Ascites volume (ml)

PBS

AMD3100

PBS

AMD3100

F

Omentum

Colon

Peritoneal Wall

Diaphragm

Liver

Mesentery

Spleen

Stomach

G

Disseminated

Limited

Localized

Mice (n)

H

I

Percent Survival

Days Post-Ascites

Percent Survival

Days Post-Ascites

Mice (n)
Figure 3

A

B

Vessel density/mm²

Tumor Vessels

PBS  AMD3100  RNAi

Figure 3
Figure 4

A

Apoptotic Cells

Negative Control   PBS   AMD3100

B

C

Apoptotic cell count/mm²

PBS   AMD3100

Figure 4
Figure 5

A

B

C

D

E

F

CD8+ cell count /mm²

Negative Control PBS AMD3100 RNAi

Anti-CD8

Anti-FoxP3

PBS

AMD3100

RNAi

CD8+ cell count /mm²

FoxP3+ cell count /mm²

PBS AMD3100 RNAi

FoxP3+ cell count /mm²

PBS AMD3100 RNAi

PBS AMD3100 RNAi

CD4+CD25+

FoxP3+

Thymus Spleen

CD8+/FoxP3+ ratio

PBS AMD3100 RNAi

PBS AMD3100 RNAi

**

**

on April 19, 2017. © 2011 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from cancerres.aacrjournals.org on April 19, 2017. © 2011 American Association for Cancer Research.
Figure 6

A

CD4-GrB+ (% of parent)

Lysed | Her2/neu

PBS | AMD3100

B

CD8-GrB+ (% of parent)

Lysed | Her2/neu

PBS | AMD3100

C

CD4-GrB+ (% of total)

PBS Lysed | PBS Her2/neu | AMD Lysed | AMD Her2/neu

D

Negative Control

CXCL12 | CXCL12 + AMD3100

Transmigration Index

Non-Depleted | Depleted

E

Depleted

Non-Depleted

CD8+ CXCR4+

Percentage of Max

CXCL12

F

Percentage of Max

CD8+ CXCR4+

G

Transmigration Index

50ng/ml | 500ng/ml | 5μg/ml

CXCL12 | PTX | AMD3100

H

Transmigration Index

5ng/ml | 50ng/ml | 500ng/ml | 5μg/ml

CXCL12 | CXCL12 + AMD3100

I

Transmigration Index

5ng/ml | 50ng/ml | 500ng/ml | 5μg/ml

CXCL12 | CXCL12 + AMD3100
Figure 7

A

![Graph showing T-cell counts](A)

B

![Histograms showing percentage of Max](B)
CXCL12/CXCR4 blockade induces multimodal anti-tumor effects and prolongs survival of immunocompetent mice with ovarian cancer

Elda Righi, Satoshi Kashiwagi, Jianping Yuan, et al.

Cancer Res Published OnlineFirst July 8, 2011.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-3143

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/07/08/0008-5472.CAN-10-3143.DC1

Author Manuscript Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.